LuMind IDSC Statement on FDA Approval of Leqembi
Last week the FDA announced a full approval of a new drug called Leqembi to…
Kim WarrenJuly 13, 2023
Over-Medication and Older Adults with Intellectual Disability: Risks for Brain Health
"Over-Medication and Older Adults with Intellectual Disability: Risks for Brain Health," cautions users and families…
Advisory on Long-COVID and Impact on Cognitive Function in Adults with Intellectual Disability
The purpose of this advisory is to provide background information on newly recognized cognitive impairments,…
Capetivate capetivateNovember 8, 2022
LuMind IDSC signs on to NTG statement re: Aduhelm
“It is unknown to what degree aducanumab (Aduhelm) may help people with Down syndrome, as…
Rigsby RigsbyOctober 27, 2021
LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage
LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage
LuMind IDSC has joined the National Down Syndrome Society (NDSS) and The National Task Group…
Rigsby RigsbyOctober 27, 2021